Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: The measurement of urinary sodium excretion provides valuable information about an individual's sodium balance and can help in the management of various medical conditions. However, the collection of 24-hour urine samples is subject to errors. Spot urine sodium (uNa) measurements are a reliable alternative to 24-hour urine collections for estimating urinary sodium excretion.

Objective: To assess whether 24-h urinary sodium excretion (24 h uNa) can be estimated from spot samples in adult patients who attend hospital clinics.

Design And Methods: A cross-sectional study with a development (284 patients) and a validation cohort (229 patients) was conducted at our hospital. A multivariate linear regression model was built which was compared with former models. Concordance analyses and comparison of the ability to correctly classify each patient against a prespecified uNa cutoff value of 130 mmol/24 h were performed, assessed by the C-statistic.

Results: The model was well calibrated (slope [95% confidence interval] in internal validation: 0.965 [0.947-0.987], showing good discrimination, and performed robustly in an external validation cohort (slope: 0.811 [0.675-0.946]). The mean bias between the measured and the estimated 24 h uNa by NaRYC was 24.85 mmol/24 h [17.06-32.63]. The NaRYC had the highest values of Pearson coefficient (0.613 P < .0001), accuracy (the percentage of estimated 24 h uNa results within 30% deviation of measured 24 h uNa): 56.8%, and area under the receiver operating characteristic curve: 0.822 [0.766-0.869] as compared to other seven equations.

Conclusion: Although the mean bias of the results is quite acceptable, the variability observed in the 95% confidence interval makes not recommend the general use of a spot as a substitute of the 24-hour urine in order to estimate the total urine excretion of Na in a single subject basis.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jrn.2024.09.004DOI Listing

Publication Analysis

Top Keywords

urinary sodium
16
sodium excretion
12
24-hour urine
12
spot urine
8
urine samples
8
samples adult
8
adult patients
8
validation cohort
8
estimated una
8
sodium
6

Similar Publications

Introduction Nephrogenic diabetes insipidus (NDI) is a rare condition caused by renal resistance to the action of antidiuretic hormone (ADH) at the level of the distal tubule, resulting in impaired urinary concentration and consequent polyuria. NDI may be hereditary, most commonly X-linked due to AVPR2 gene mutations, or acquired. Objective To characterize the clinical features, management strategies, and outcomes of patients with NDI followed at a tertiary pediatric nephrology center.

View Article and Find Full Text PDF

This systematic review explores the impact of diuretic timing and strategy on outcomes in patients with acute decompensated heart failure (ADHF). A total of seven studies were included, comprising randomized controlled trials (RCTs), pre-specified sub-analyses, and observational data. Early administration of intravenous loop diuretics, particularly within the first 60 to 90 minutes of hospital arrival, was generally associated with improved short-term outcomes, including reduced in-hospital and 30-day mortality.

View Article and Find Full Text PDF

Shiga toxin (Stx) is a virulence factor produced by serotype 1 and Stx-producing (STEC). It causes severe renal damage, leading to hemolytic uremic syndrome (HUS). The main target organ of Stx, the kidney, plays a role in maintaining water homeostasis in the body by increasing an osmotic gradient from the cortex to the medulla.

View Article and Find Full Text PDF

The complement component C3, factor B (FB) and factor D (FD) belong to the alternative complement pathway and have been identified in urine samples from nephrotic mice. However, it is not yet known whether these factors are involved in mediating sodium retention in nephrotic syndrome (NS). Here we used a genetic mouse model of NS based on an inducible podocin deletion ( ).

View Article and Find Full Text PDF

Objective:  Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with obesity, leading to increased risks of cardiovascular and renal complications. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a promising therapeutic agent for improving glycemic control and promoting weight reduction. However, evaluating its safety and efficacy in obese T2DM patients remains essential, particularly in real-world clinical settings.

View Article and Find Full Text PDF